KRAS and colorectal cancer: In clinical settings, PBK/TOPK expression is an unfavorable prognostic indicator in patients with sporadic colorectal cancer with mutations in the proto-oncogene KRAS or BRAF and in patients with metastatic disease experiencing a response to anti-EGFR monoclonal antibody therapies [31,38].